FR2510606A1 - Procede d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application a la preparation de vaccins - Google Patents
Procede d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application a la preparation de vaccins Download PDFInfo
- Publication number
- FR2510606A1 FR2510606A1 FR8114842A FR8114842A FR2510606A1 FR 2510606 A1 FR2510606 A1 FR 2510606A1 FR 8114842 A FR8114842 A FR 8114842A FR 8114842 A FR8114842 A FR 8114842A FR 2510606 A1 FR2510606 A1 FR 2510606A1
- Authority
- FR
- France
- Prior art keywords
- capsular
- polyosides
- culture
- polysaccharide
- retentate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 229960005486 vaccine Drugs 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title description 5
- 239000012528 membrane Substances 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 11
- 230000000813 microbial effect Effects 0.000 claims abstract description 8
- 230000002163 immunogen Effects 0.000 claims abstract description 7
- 150000002632 lipids Chemical class 0.000 claims abstract description 6
- 150000004676 glycans Chemical class 0.000 claims description 57
- 239000005017 polysaccharide Substances 0.000 claims description 57
- 229920001282 polysaccharide Polymers 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 16
- 239000012465 retentate Substances 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000008346 aqueous phase Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 239000012071 phase Substances 0.000 claims description 7
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 6
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 230000003698 anagen phase Effects 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 1
- 229940045505 klebsiella pneumoniae Drugs 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 abstract 6
- 230000000717 retained effect Effects 0.000 abstract 4
- 239000007791 liquid phase Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000000605 extraction Methods 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 150000008163 sugars Chemical class 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 241000194017 Streptococcus Species 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000011026 diafiltration Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- OAABHEHWRQAHEJ-UHFFFAOYSA-N butan-1-ol;chloroform Chemical compound ClC(Cl)Cl.CCCCO OAABHEHWRQAHEJ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000003067 hemagglutinative effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010059712 Pronase Proteins 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001492 haemagglutinating effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108010009004 proteose-peptone Proteins 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- GXDQRUABXSGKQL-MCDZGGTQSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GXDQRUABXSGKQL-MCDZGGTQSA-N 0.000 description 1
- BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 description 1
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710092599 Protein 7.7 Proteins 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940068840 d-biotin Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- -1 ethanol Chemical compound 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N hexopyranose Chemical compound OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000009991 pite Nutrition 0.000 description 1
- 244000293655 pite Species 0.000 description 1
- 229940124733 pneumococcal vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229940052714 riboflavin 1 mg Drugs 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000002333 serotherapy Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940088174 thiamine 1 mg Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polyesters Or Polycarbonates (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8114842A FR2510606A1 (fr) | 1981-07-30 | 1981-07-30 | Procede d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application a la preparation de vaccins |
| IE1705/82A IE53582B1 (en) | 1981-07-30 | 1982-07-15 | Process for the production of capsular polyosides,capsular polyosides obtained thereby,and their application to the preparation of vaccines |
| EP82401343A EP0071515B1 (fr) | 1981-07-30 | 1982-07-19 | Procédé d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application à la préparation de vaccins |
| DE8282401343T DE3267160D1 (en) | 1981-07-30 | 1982-07-19 | Process for producing capsular polyosides, capsular polyosides so obtained and their use in the preparation of vaccines |
| AT82401343T ATE16244T1 (de) | 1981-07-30 | 1982-07-19 | Verfahren zur herstellung von kapselpolyosiden, so erhaltene kapselpolyosiden und ihre verwendung fuer die herstellung von vakzinen. |
| DK327182A DK327182A (da) | 1981-07-30 | 1982-07-21 | Indkapslede polyoxider og fremgangsmaade til fremstilling deraf |
| PT75301A PT75301B (fr) | 1981-07-30 | 1982-07-23 | Procede d'obtention de polyosides capsulaires appliques a la preparation de vaccins |
| CA000408233A CA1206905A (en) | 1981-07-30 | 1982-07-28 | Process for the production of capsular polyosides and capsular polyosides obtained thereby |
| NO822592A NO159394C (no) | 1981-07-30 | 1982-07-28 | Fremgangsmaate for fremstilling av immunogene kapselformede polyosider fra kapselbakterier. |
| ES514496A ES8305827A1 (es) | 1981-07-30 | 1982-07-29 | "un procedimiento de obtencion de poliosidos capsulares inmunogenos". |
| DD82242065A DD202623A5 (de) | 1981-07-30 | 1982-07-29 | Verfahren zur herstellung von sporen-polyosiden |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8114842A FR2510606A1 (fr) | 1981-07-30 | 1981-07-30 | Procede d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application a la preparation de vaccins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2510606A1 true FR2510606A1 (fr) | 1983-02-04 |
| FR2510606B1 FR2510606B1 (https=) | 1984-10-26 |
Family
ID=9261011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8114842A Granted FR2510606A1 (fr) | 1981-07-30 | 1981-07-30 | Procede d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application a la preparation de vaccins |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0071515B1 (https=) |
| AT (1) | ATE16244T1 (https=) |
| CA (1) | CA1206905A (https=) |
| DD (1) | DD202623A5 (https=) |
| DE (1) | DE3267160D1 (https=) |
| DK (1) | DK327182A (https=) |
| ES (1) | ES8305827A1 (https=) |
| FR (1) | FR2510606A1 (https=) |
| IE (1) | IE53582B1 (https=) |
| NO (1) | NO159394C (https=) |
| PT (1) | PT75301B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0238739B1 (en) * | 1986-03-27 | 1992-02-05 | Swiss Serum and Vaccine Institute Berne | Klebsiella capsular polysaccharide vaccine |
| US6426074B1 (en) * | 1997-03-19 | 2002-07-30 | The Brigham And Women's Hospital Inc. | Group B Streptococcus vaccine |
| NZ521343A (en) * | 2000-03-16 | 2005-03-24 | Philadelphia Children Hospital | Modulating production of pneumococcal capsular polysaccharide |
| NZ511680A (en) | 2001-05-14 | 2004-07-30 | Univ Waikato | Method for preparing nucleic acid or DNA samples and a DNA extraction process using thermophilic proteases |
| GB0522303D0 (en) * | 2005-11-01 | 2005-12-07 | Chiron Srl | Culture method |
| US8398985B2 (en) | 2007-04-23 | 2013-03-19 | Serum Institute Of India Ltd. | Antigenic polysaccharides and process for their preparation |
| WO2011148382A1 (en) | 2010-05-28 | 2011-12-01 | Biological E Limited | An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol. |
| WO2011151841A1 (en) * | 2010-05-31 | 2011-12-08 | Panacea Biotec Limited | Fermentation process for streptococcus pneumoniae |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| ES3024474T3 (en) | 2016-12-30 | 2025-06-04 | Vaxcyte Inc | Polypeptide-antigen conjugates with non-natural amino acids |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| CN120202227A (zh) | 2022-09-19 | 2025-06-24 | 生物学E有限公司 | 纯化荚膜多糖的方法 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2166963A (en) * | 1936-11-19 | 1939-07-25 | Sharp & Dohme Inc | Antigenic polysaccharide complex |
| US2528972A (en) * | 1947-05-15 | 1950-11-07 | Western Reserve University | Prophylactic toxoid compound and method of making same |
| EP0001945A1 (fr) * | 1977-10-27 | 1979-05-16 | Roussel-Uclaf | Nouveaux polysaccharides extraits de corps microbiens d'Haemophilus Influenzae, leur procédé de préparation et les compositions pharmaceutiques les renfermant |
| EP0002404A1 (en) * | 1977-11-28 | 1979-06-13 | Merck & Co. Inc. | Pneumococcal vaccine and a process for its preparation |
| EP0017322A1 (en) * | 1979-03-19 | 1980-10-15 | American Cyanamid Company | Stabilization of capsular polysaccharides |
| US4264764A (en) * | 1979-01-12 | 1981-04-28 | Merck & Co., Inc. | Meningitis vaccine |
| EP0030166A1 (en) * | 1979-09-24 | 1981-06-10 | Merck & Co. Inc. | Vaccine composition for dental caries |
| US4307080A (en) * | 1979-09-24 | 1981-12-22 | Merck & Co., Inc. | Meningitis vaccine |
-
1981
- 1981-07-30 FR FR8114842A patent/FR2510606A1/fr active Granted
-
1982
- 1982-07-15 IE IE1705/82A patent/IE53582B1/en unknown
- 1982-07-19 EP EP82401343A patent/EP0071515B1/fr not_active Expired
- 1982-07-19 DE DE8282401343T patent/DE3267160D1/de not_active Expired
- 1982-07-19 AT AT82401343T patent/ATE16244T1/de not_active IP Right Cessation
- 1982-07-21 DK DK327182A patent/DK327182A/da not_active Application Discontinuation
- 1982-07-23 PT PT75301A patent/PT75301B/pt not_active IP Right Cessation
- 1982-07-28 CA CA000408233A patent/CA1206905A/en not_active Expired
- 1982-07-28 NO NO822592A patent/NO159394C/no unknown
- 1982-07-29 DD DD82242065A patent/DD202623A5/de unknown
- 1982-07-29 ES ES514496A patent/ES8305827A1/es not_active Expired
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2166963A (en) * | 1936-11-19 | 1939-07-25 | Sharp & Dohme Inc | Antigenic polysaccharide complex |
| US2528972A (en) * | 1947-05-15 | 1950-11-07 | Western Reserve University | Prophylactic toxoid compound and method of making same |
| EP0001945A1 (fr) * | 1977-10-27 | 1979-05-16 | Roussel-Uclaf | Nouveaux polysaccharides extraits de corps microbiens d'Haemophilus Influenzae, leur procédé de préparation et les compositions pharmaceutiques les renfermant |
| EP0002404A1 (en) * | 1977-11-28 | 1979-06-13 | Merck & Co. Inc. | Pneumococcal vaccine and a process for its preparation |
| US4264764A (en) * | 1979-01-12 | 1981-04-28 | Merck & Co., Inc. | Meningitis vaccine |
| EP0017322A1 (en) * | 1979-03-19 | 1980-10-15 | American Cyanamid Company | Stabilization of capsular polysaccharides |
| EP0030166A1 (en) * | 1979-09-24 | 1981-06-10 | Merck & Co. Inc. | Vaccine composition for dental caries |
| US4307080A (en) * | 1979-09-24 | 1981-12-22 | Merck & Co., Inc. | Meningitis vaccine |
Non-Patent Citations (6)
| Title |
|---|
| BIOCHEMISTRY, vol. 3, no. 10, 25 octobre 1964, pages 1548-1550, New York (USA); M.HEIDELBERGER et al.: "The specific polysaccharide of type XVIIIA Pneumococcus". * |
| MICROBIOLOGY ABSTRACTS, vol. 7, no. 6, juin 1972, section B, no. 5070, page 165, Boston, Mass. (USA); P.ANDERSON et al.: "Immunization of humans with polyribophosphate, the capsular entigen of Hemophilus influenzae, type b". * |
| THE JOURNAL OF IMMUNOLOGY, vol. 110, no. 1, janvier 1973, pages 262-268, New York (USA); D.L.KASPER et al.: "Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1 (L): NM and group B Neisseria meningitidis". * |
| THE JOURNAL OF IMMUNOLOGY, vol. 112, no. 2, février 1974, pages 649-55, (USA);M.ARGAMAN et al.: "Polyribitol-phosphate: an antigen of four gram-positive bacteria cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b". * |
| UNLISTED DRUGS, vol. 15, no. 11, novembre 1963, page 84, New York (USA); Référence n: colanic acid. * |
| UNLISTED DRUGS, vol. 28, no. 12, décembre 1976, page 205, New York (USA); Référence d: SSS 8. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES514496A0 (es) | 1983-04-16 |
| FR2510606B1 (https=) | 1984-10-26 |
| EP0071515A1 (fr) | 1983-02-09 |
| ATE16244T1 (de) | 1985-11-15 |
| CA1206905A (en) | 1986-07-02 |
| PT75301A (fr) | 1982-08-01 |
| EP0071515B1 (fr) | 1985-10-30 |
| DE3267160D1 (en) | 1985-12-05 |
| PT75301B (fr) | 1984-07-31 |
| IE53582B1 (en) | 1988-12-21 |
| DD202623A5 (de) | 1983-09-28 |
| NO822592L (no) | 1983-01-31 |
| ES8305827A1 (es) | 1983-04-16 |
| IE821705L (en) | 1983-01-30 |
| NO159394C (no) | 1988-12-21 |
| DK327182A (da) | 1983-01-31 |
| NO159394B (no) | 1988-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dubos et al. | Preparation and properties of Shiga toxin and toxoid | |
| US4271147A (en) | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same | |
| RU2194531C2 (ru) | Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины | |
| US4687738A (en) | Method for the production of HA fraction containing protective antigens of Bordetella pertussis and pertussis vaccine | |
| JP2911603B2 (ja) | 新規な弱毒化シュードモナス・エルギノーザ株 | |
| FR2475900A1 (fr) | Complexe vaccinal contenant un antigene specifique et vaccin le contenant | |
| FR2510606A1 (fr) | Procede d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application a la preparation de vaccins | |
| EP0088303A2 (fr) | Procédé de préparation de complexes polysaccharide-protéine de capsules bactériennes, produits obtenus et compositions immunogènes les contenant | |
| EP0041897B1 (en) | Polysaccharide antigen from streptococcus and vaccines | |
| JP2549225B2 (ja) | 百日咳菌外膜蛋白質の精製方法 | |
| US4207414A (en) | Polysaccharide antigens | |
| CA1103155A (fr) | Vaccins acellulaires perfectionnes contenant des polysaccharides capsulaires | |
| US4349540A (en) | Process for preparing vaccines based on antigenic ribosomal fractions | |
| US4220584A (en) | E. coli enterotoxin vaccine for veterinary and human use | |
| JPH05219942A (ja) | 細菌クロストリジウム・ヒストリチカムの変異株、その製造法及びその用途 | |
| US4367223A (en) | Vaccine against Group B streptococci | |
| JPS58164514A (ja) | 免疫刺激性プロテオグリカンおよびその製造方法 | |
| US4356263A (en) | Method of making a polysaccharide vaccine | |
| EP0374178A1 (en) | PROCESS FOR THE PREPARATION OF ACELLULAR VETERINARY VACCINES AGAINST GRAM-NEGATIVE NON-ENTERIC PATHOGENIC BACILLAS. | |
| US5225194A (en) | Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases | |
| JPS6211090A (ja) | トレポネマ・ハイオジセンテリアエの生育方法 | |
| US4367221A (en) | Immunization against Group B streptococci | |
| RU2143280C1 (ru) | Способ получения o-антигена холерного очищенного | |
| DE2845745C2 (https=) | ||
| US4136181A (en) | Vaccines against oedema disease of piglets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |